Curet Myriam, EVP and Chief Medical Officer, has been a consistent seller of Intuitive Surgical (ISRG) stock over the past several months, with no open-market purchases recorded in her recent Form 4 filings. Her trading activity is heavily weighted toward sales, totaling approximately $12.7 million across all transactions, versus just $803 in buys. The recent window—spanning late January through mid-March 2026—shows seven open-market sales (code S) of ISRG shares, ranging from roughly $51,900 to $2.3 million, with the largest single disposition occurring on March 3, 2026. These sales were frequently paired with option exercises (code M) and shares withheld to cover taxes (code F), a pattern typical of a compensation-driven liquidation rather than a discretionary bet against the stock.
Beyond ISRG, Curet holds positions in three other medical device companies—MOBI, STXS, and INSP—but her filings there reflect only grants or awards (code A) with zero dollar value, indicating equity compensation rather than active trading. Her most recent transactions, dated July 30, 2026, are MOBI awards, while the last ISRG sale occurred on March 10, 2026. The absence of any open-market purchases (code P) across her entire filing history underscores a clear selling bias, though the mechanical nature of many transactions—option exercises and tax withholdings—suggests routine portfolio management tied to her executive compensation structure. The data shows no recent buying conviction, with all discretionary activity directed toward reducing her ISRG stake.
AI-assisted summary